{"id":888625,"date":"2025-09-23T08:03:06","date_gmt":"2025-09-23T12:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/"},"modified":"2025-09-23T08:03:06","modified_gmt":"2025-09-23T12:03:06","slug":"amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/","title":{"rendered":"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%"},"content":{"rendered":"

\nImportant ophthalmic treatment for patients and expected to be a key growth driver for Amneal\u2019s Affordable Medicines segment
\n<\/h2>\n
\n

BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (\u201cAmneal\u201d or the \u201cCompany\u201d) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company\u2019s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN\u00ae<\/sup> (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company.<\/p>\n

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.<\/p>\n

\u201cWe are pleased to add another key ophthalmic therapy to our Affordable Medicines portfolio,\u201d said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer \u2013 Affordable Medicines. \u201cAs the prevalence of glaucoma continues to rise, particularly among the aging population, it is critical that patients and providers have affordable access to effective treatments such as bimatoprost. This represents our most recent complex new product approval this year and an important growth driver for our Affordable Medicines segment.\u201d<\/p>\n

The most common adverse reaction associated with bimatoprost ophthalmic solution 0.01% is conjunctival hyperemia. For prescribing information, see package insert here<\/a>.<\/p>\n

According to IQVIA\u00ae<\/sup> U.S. annual sales for bimatoprost ophthalmic solution 0.01% for the 12 months ended July 2025 were approximately $685 million.<\/p>\n

Note: LUMIGAN\u00ae<\/sup> is a registered trademark of Allergan, Inc., an AbbVie company.<\/p>\n

\n About Amneal<\/strong>
\n
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit\u00a0www.amneal.com<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

\n Cautionary Statement on Forward-Looking Statements<\/strong>
\n
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management\u2019s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as \u201cplans,\u201d \u201cexpects,\u201d \u201cwill,\u201d \u201canticipates,\u201d \u201cestimates,\u201d and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company\u2019s filings with the Securities and Exchange Commission, including under Item 1A, \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.<\/p>\n

\n Investor Contact <\/strong>
\n
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal\u2019s Affordable Medicines segment BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (\u201cAmneal\u201d or the \u201cCompany\u201d) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company\u2019s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN\u00ae (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. \u201cWe are pleased to add another key ophthalmic therapy … <\/p>\n

Continue reading “Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-888625","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAmneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal\u2019s Affordable Medicines segment BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (\u201cAmneal\u201d or the \u201cCompany\u201d) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company\u2019s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN\u00ae (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. \u201cWe are pleased to add another key ophthalmic therapy … Continue reading "Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T12:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%\",\"datePublished\":\"2025-09-23T12:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/\"},\"wordCount\":585,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/\",\"name\":\"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=\",\"datePublished\":\"2025-09-23T12:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/","og_locale":"en_US","og_type":"article","og_title":"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - Market Newsdesk","og_description":"Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal\u2019s Affordable Medicines segment BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (\u201cAmneal\u201d or the \u201cCompany\u201d) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company\u2019s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN\u00ae (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. \u201cWe are pleased to add another key ophthalmic therapy … Continue reading \"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-23T12:03:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%","datePublished":"2025-09-23T12:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/"},"wordCount":585,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/","name":"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01% - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=","datePublished":"2025-09-23T12:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzMzUyMiM3MTU5Mzk2IzIxOTA3Mzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/amneal-receives-u-s-fda-approval-for-bimatoprost-ophthalmic-solution-0-01\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=888625"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/888625\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=888625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=888625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=888625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}